专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004073611A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2004073611A2
公开(公告)日：2004-09-02
申请号：PCT/US2004/003718
申请日：2004-02-09
申请人： WELLSTAT THERAPEUTICS CORPORATION , HODGE, Kirvin, L. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
发明人： HODGE, Kirvin, L. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： A61K
CPC分类号： C07C69/734 , A61K31/192 , A61K31/24 , C07C59/68 , C07C65/24 , C07C69/76 , C07C69/92
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1; t is 0 or 1; R 2 is alkyl from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloaldyl having from 3 to 6 ring carbon atoms wherein the cycloaldyl is unsubstitited or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compounds of formula (I) by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
摘要翻译：公开了用于治疗各种代谢疾病如胰岛素抵抗综合征，糖尿病，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化的药剂。式（I）其中n为1或2; m为0,1,2,4或5; q为0或1; t为0或1; R 2是1至3个碳原子的烷基; R 3是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; A是未取代或被1或2个选自以下的基团取代的苯基：卤素，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基; 或具有3至6个环碳原子的环戊烯基，其中所述环烯基未被取代或一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与其余的式（I）化合物共价结合; 和R 1是氢或具有1或2个碳原子的烷基。或者，当R 1是氢时，生物活性剂可以是式（I）化合物的药学上可接受的盐。

2. 发明申请

WO2004093806A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2004093806A2
公开(公告)日：2004-11-04
申请号：PCT/US2004/012142
申请日：2004-04-20
申请人： WELLSTAT THERAPEUTICS CORPORATION , HODGE, Kirvin, L. , KAUFMAN, Robert, J. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
发明人： HODGE, Kirvin, L. , KAUFMAN, Robert, J. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： A61K
CPC分类号： C07C69/734 , A61K31/235
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 2 or 3; q is 0 or 1; t is 0 or 1; R 2 is alkyl having from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
摘要翻译：公开了用于治疗各种代谢疾病如胰岛素抵抗综合征，糖尿病，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化的药剂。式（I）其中n为1或2; m为2或3; q为0或1; t为0或1; R 2是具有1至3个碳原子的烷基; R 3是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; A是未取代的或被1或2个选自：卤素，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基取代的苯基; 或具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式I化合物的其余部分共价结合; 和R 1是氢或具有1或2个碳原子的烷基。或者，当R 1是氢时，生物活性剂可以是式（I）化合物的药学上可接受的盐。

3. 发明授权

EP1601251B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 有权
公开(公告)号：EP1601251B1
公开(公告)日：2014-11-12
申请号：EP04709467.7
申请日：2004-02-09
申请人： Wellstat Therapeutics Corporation
发明人： HODGE, Kirvin, L. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： A61K31/24 , C07C65/24 , C07C69/734 , C07C69/76 , C07C69/92 , C07C59/68 , A61K31/192 , A61P5/50 , A61P3/06 , A61P9/10
CPC分类号： C07C69/734 , A61K31/192 , A61K31/24 , C07C59/68 , C07C65/24 , C07C69/76 , C07C69/92

4. 发明授权

EP1618086B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 失效
标题翻译：化合物的代谢疾病的治疗
公开(公告)号：EP1618086B1
公开(公告)日：2009-12-02
申请号：EP04750364.4
申请日：2004-04-20
申请人： Wellstat Therapeutics Corporation
发明人： HODGE, Kirvin, L. , KAUFMAN, Robert, J. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： C07C229/00 , C07C205/00 , C07C63/00 , A01N43/12 , A61K31/192 , A61P3/04 , A61P3/06 , A61P3/08 , A61P3/10 , A61P1/16 , A61P9/10 , A61P9/12
CPC分类号： C07C69/734 , A61K31/235
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 2 or 3; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

5. 发明公开

EP1618086A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 失效
标题翻译：化合物的代谢疾病的治疗
公开(公告)号：EP1618086A2
公开(公告)日：2006-01-25
申请号：EP04750364.4
申请日：2004-04-20
申请人： Wellstat Therapeutics Corporation
发明人： HODGE, Kirvin, L. , KAUFMAN, Robert, J. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： C07C229/00 , C07C205/00 , C07C63/00 , A01N43/12
CPC分类号： C07C69/734 , A61K31/235
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 2 or 3; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

6. 发明公开

EP1601251A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 有权
标题翻译：化合物的代谢疾病的治疗
公开(公告)号：EP1601251A2
公开(公告)日：2005-12-07
申请号：EP04709467.7
申请日：2004-02-09
申请人： Wellstat Therapeutics Corporation
发明人： HODGE, Kirvin, L. , LEE, Albert , SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： A01N37/00
CPC分类号： C07C69/734 , A61K31/192 , A61K31/24 , C07C59/68 , C07C65/24 , C07C69/76 , C07C69/92
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 4, or 5; q is 0 or 1; t is 0 or 1; R 2 is alkyl having from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.

7. 发明申请

WO2007081689A2 END-TO-END ARCHITECTURE FOR UNIVERSAL MOBILITY AND WIRELESS-AWARE TRANSPORT 审中-公开
标题翻译：通用移动和无线传输的终端架构
公开(公告)号：WO2007081689A2
公开(公告)日：2007-07-19
申请号：PCT/US2007/000044
申请日：2007-01-04
申请人： IST INTERNATIONAL INC. , IYER, Mahadevan , LEE, Albert
发明人： IYER, Mahadevan , LEE, Albert
IPC分类号： H04L12/50
CPC分类号： H04L12/2856 , H04L29/12311 , H04L29/1249 , H04L61/2084 , H04L61/256 , H04L69/16 , H04W36/0033 , H04W80/06 , H04W80/10
摘要： Embodiments of the present disclosure may provide a network node that communicates data with a second network node over a plurality of networks. The network node includes a fixed micronode and a mobile micronode. The fixed micronode sends a packet to the mobile micronode, where the packet includes a portion of the data and a fixed connection-tuple. The mobile micronode includes replaces the fixed connection-tuple in the packet with a mobile connection-tuple, and forwards the replaced packet to the second network node.
摘要翻译：本公开的实施例可以提供在多个网络上与第二网络节点通信数据的网络节点。网络节点包括固定的微码和移动微码。固定的微米码将数据包发送到移动微米级，其中数据包包括一部分数据和固定的连接元组。移动微码包括用移动连接元组替换分组中的固定连接元组，并将替换的分组转发到第二网络节点。

8. 发明申请

WO2007056430A3 SECURITY SYSTEM ENHANCEMENT DEVICE KEY 审中-公开
公开(公告)号：WO2007056430A3
公开(公告)日：2007-05-18
申请号：PCT/US2006/043440
申请日：2006-11-07
申请人： HONEYWELL INTERNATIONAL, INC. , YUK, Howard , LI, Tony, T. , LEE, Albert
发明人： YUK, Howard , LI, Tony, T. , LEE, Albert
IPC分类号： B60R25/10
摘要： A system for enabling or disabling one or more security system features of a security system platform allows manufactures to produce one security system platform. Such a system includes a controller configured for controlling the one or more security system features and an interface in communication with the controller. The system further includes an electronic device key for storing configuration data, the electronic device key being configured to electrically mate with the interface to establish communication between the electronic device key and the controller to transmit the configuration data to the controller to instruct the controller to enable or disable the one or more security system features of the security system platform.

9. 发明申请

WO2006058257A2 METHOD AND APPARATUS FOR SETTING A TCP RETRANSMISSION TIMER 审中-公开
标题翻译：用于设置TCP重新定时器的方法和设备
公开(公告)号：WO2006058257A2
公开(公告)日：2006-06-01
申请号：PCT/US2005/042820
申请日：2005-11-23
申请人： IST INTERNATIONAL, INC. , IYER, Mahadevan , LEE, Albert
发明人： IYER, Mahadevan , LEE, Albert
CPC分类号： H04L69/16 , H04L47/10 , H04L69/163 , H04W80/06
摘要： A retransmission timer of a Transmission Control Protocol (TCP) session is set based at least in part on the predicted mean round trip time differential of the TCP session. For example, in one embodiment, after receiving a non-duplicate acknowledgment, the predicted mean round trip time differential of the TCP session would be determined and used to further determine the predicted round trip time of the next transmitted data segment. In one embodiment, the predicted round trip time of the next tranmitted data segment would be used to determine a retransmission timout, the value of which would be inserted into a retransmission timer.
摘要翻译：至少部分地基于TCP会话的预测的平均往返时间差来设置传输控制协议（TCP）会话的重传定时器。例如，在一个实施例中，在接收到非重复确认之后，将确定TCP会话的预测平均往返时间差，并用于进一步确定下一个发送数据段的预测往返时间。在一个实施例中，下一个发送的数据段的预测往返时间将用于确定其值将被插入到重传定时器中的重传定时。

10. 发明申请

WO2009055700A3 WINDSHIELD WIPER ASSEMBLY HAVING A BODY MADE OF SPRING STEEL 审中-公开
公开(公告)号：WO2009055700A3
公开(公告)日：2009-04-30
申请号：PCT/US2008/081159
申请日：2008-10-24
申请人： ALBEREE PRODUCTS, INC. , LEE, Albert
发明人： LEE, Albert
IPC分类号： B60S1/38 , B60S1/32
摘要： A windshield wiper assembly includes a pair of leaf spring elements supported generally parallel to each other with a space therebetween. Each of the leaf spring elements includes a longitudinal slot formed therein at opposite ends thereof. A support bracket maintains the pair of leaf spring elements in generally parallel spaced apart relation to support the squeegee therebetween. A pair of end caps is mounted on opposite ends of the pair of spring steel elements. Each of the end caps includes a pair of detents for engaging the longitudinal slots formed in the spring steel elements and a pair of slots for receiving the ends of the spring steel elements threrethrough. A longitudinal length of each of the detents is shorter than a longitudinal length of the longitudinal slots formed in the spring steel elements, so that the spring steel elements can slide with respect to the end caps.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式